CLINICAL AND HISTOLOGIC FEATURES OF UTERINE MYOMA IN REPRODUCTIVE-AGE WOMEN UNDER THE TREATMENT BY SELECTIVE PROGESTERONE RECEPTOR MODULATORS
Igor’ Olegovich MARINKIN1, Lyudmila Anatol’evna PIVEN’2, Alexandr Viktorovich VOLCHEK2, Dmitriy Alexandrovich SOLYANIKOV3, Yuliya Viktorovna ZENINA1, Elena Semenovna MIKHAYLOVA1, Vladimir Vilor’evich OMIGOV1, Svetlana Vladimirovna AIDAGULOVA1
1Novosibirsk State Medical University of Minzdrav of Russia
rector@ngmu.ru
2Novosibirsk State Medical University of Minzdrav of Russia, State Novosibirsk Regional Clinical Hospital
ludmilapiv@yandex.ru
3State Novosibirsk Regional Clinical Hospital
solyanikovda@gmail.com
Keywords: миома тела матки, миометрий, фактор роста эндотелия сосудов, селективный модулятор прогестероновых рецепторов, иммуноферментный анализ
Abstract
Aim of the study was to
investigate the clinical features of reproductive age women with uterine
body myoma and the production of vascular endothelial growth factor
(VEGF) in the dominant myoma node and perifocal myometrium under the
preoperative use of ulipristal acetate (UA). Material and methods. 140
samples of 35 women surgical material were studied, VEGF content in the
incubation medium of samples of myoma and myometrium was measured using
enzyme-linked immunosorbent assay. Results and discussion. The treatment
by UA before myoma surgery according to the standard regimen per 5 mg
daily for 13 weeks deals with significantly reduced production of VEGF
in the dominant myoma node compared to perifocal myometrium ( p <
0.001), which is similar to patients of the control group. However, when
comparing tumor nodes, a significantly lower content of VEGF was
revealed in the UA-group ( p = 0.026); unlike the perifocal myometrium
samples. Conclusion. The use of a selective modulator of progesterone
receptors down-regulates the production of VEGF by the cells of the
myoma nodes and doesn’t impact on the perifocal myometrium.
|
